• Doxorubicin Hydrochloride Research Workflow

  2026-09-30

  Build more informative cancer chemotherapy research workflows with Doxorubicin hydrochloride, from dose–response and apoptosis assays to mechanistic cardiotoxicity models. This guide connects practical assay design with a mouse study showing how oxidative stress, ferroptosis-related injury, and cardiac function can be evaluated together.

• Homer1a–Caspase-6 Signaling in Inflammatory Pain

  2026-09-30

  The reference study identifies a Homer1a/caspase-6/tumor necrosis factor-alpha axis that links synaptic signaling with microglial inflammation and thermal hypersensitivity. Pharmacologic inhibition and Homer1a overexpression both reduced pain-related outcomes in rats, supporting caspase-6 as a mechanistic node while leaving important questions about cell specificity, chronic pain, and translation unresolved.

• Spatially Concentrated ABEs Correct PLP1 Mutations

  2026-09-29

  The 2026 Nucleic Acids Research study introduces spatially concentrated adenine base editors that improve editing in oligodendrocytes by locally enriching TadA* at genomic targets rather than simply increasing catalytic activity. An AAV-compatible editor corrected PLP1 A243V, improved Plp localization, and rescued myelination-associated phenotypes, providing a preclinical framework for Pelizaeus–Merzbacher disease research.

• Plk1 Regulation of p31comet Checkpoint Disassembly

  2026-09-29

  The reference study identifies Polo-like kinase 1 (Plk1) as a direct regulator of p31comet-mediated mitotic checkpoint complex disassembly. By phosphorylating p31comet at S102, Plk1 suppresses TRIP13-dependent Mad2 release and may prevent premature checkpoint inactivation during active mitosis.

• 5-Azacytidine Workflow for DNA Demethylation

  2026-09-28

  Build reproducible 5-Azacytidine assays that connect promoter methylation with gene reactivation, epithelial-state changes, and cancer-cell responses. This practical workflow adapts recent HNF4A gastric-cancer findings while separating broad DNMT inhibition from locus-specific causal evidence.

• Triiodothyronine (T3): Signal Control for Translation

  2026-09-28

  A translational research perspective on using Triiodothyronine to interrogate receptor-driven biology, build reproducible cellular assays, and learn from precision strategies in gene editing—without conflating distinct mechanisms or disease domains.

• Plk1 Control of p31comet in Checkpoint Disassembly

  2026-09-27

  The study identifies Polo-like kinase 1 (Plk1) as a negative regulator of p31comet-mediated mitotic checkpoint complex disassembly, linking Plk1-dependent phosphorylation at S102 to reduced p31comet activity with TRIP13. The findings suggest a mechanism for maintaining checkpoint inhibition until conditions favor checkpoint inactivation, while highlighting the need to distinguish biochemical evidence from whole-cell outcomes.

• Aclacinomycin A and Persistent rDNA Damage

  2026-09-26

  Aclacinomycin A offers a useful way to investigate how topoisomerase-linked DNA stress intersects with nucleolar damage responses. This article connects its established cytotoxic mechanisms to evidence on persistent ribosomal DNA lesions and PML-nucleolar associations, while outlining experiments that can test the connection without assuming it.

• CA-074 Me for Lysosomal and Necroptosis Assays

  2026-09-25

  Use CA-074 Me to test whether intracellular cathepsin B contributes to lysosomal damage and cell death—not merely to measure a general loss of viability. This guide connects a mechanistic necroptosis study with practical inhibitor controls, live-cell readouts, and troubleshooting for cell-based and inflammation research.

• Self-Amplifying RNA Improves Influenza B Vaccine Responses

  2026-09-25

  This study compares nucleoside-modified mRNA, self-amplifying RNA, and circular RNA vaccine approaches for seasonal influenza. In mouse challenge experiments, a low-dose trivalent self-amplifying RNA vaccine generated durable antibody responses and protected against influenza B, addressing a weakness observed with the tested mRNA vaccine.

• 5-Azacytidine and the Biology of Tumor Dormancy

  2026-09-24

  5-Azacytidine is best known as a DNA demethylation agent, but its effects can extend beyond tumor-cell killing. Explore how a 5-AzaC combination study reframes epigenetic treatment as a way to establish metastatic-cell dormancy—and how to design experiments that distinguish dormancy from cytotoxicity.

• 5-Azacytidine Workflows for Viral Mimicry Research

  2026-09-24

  Learn how to use 5-Azacytidine to probe DNA methylation, gene reactivation, and viral-mimicry responses—with a practical workflow grounded in recent PTEN-deficient glioblastoma research. The article distinguishes reported findings from suggested pilot conditions and explains how to control for cytotoxicity and combination-treatment effects.

• GSH-Responsive MOF Nanoparticles for Melanoma Therapy

  2026-09-23

  Hao and colleagues developed a glutathione-responsive metal–organic framework nanoparticle carrying indocyanine green and the PD-1/PD-L1-blocking peptide AUNP12. In the reported design, near-infrared photothermal treatment is paired with checkpoint inhibition to connect tumor-cell damage with immune activation; the findings support further study while leaving important formulation and translation questions open.

• Cisplatin A8321: Reliable Assay Workflows

  2026-09-23

  This scenario-driven guide shows how Cisplatin (SKU A8321) can support controlled viability, apoptosis, and chemotherapy resistance studies. It combines product-handling data with recent evidence on cisplatin-resistant lung adenocarcinoma models to improve interpretation and day-to-day laboratory reproducibility.

• Oseltamivir acid Research Workflow Guide

  2026-09-22

  Build more reliable influenza neuraminidase assays with Oseltamivir acid, from fresh-solution handling to resistance-aware viral readouts. The workflow also shows how human-relevant exposure studies and carefully controlled breast-cancer models can extend interpretation beyond a single antiviral endpoint.

8026 records 1/536 page Next 12345 下5页 Last page